Johnson & Johnson executive vice president and CFO Joseph Wolk joins 'Squawk Box' to discuss the company's quarterly earnings ...
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (the “Company”) (NYSE: JNJ) today announced the Company’s intent to separate its Orthopaedics business to enhance the strategic and operational ...
Johnson & Johnson CEO credits Trump tax policy for $55B US investment push, including $1B in Florida
Johnson & Johnson is betting big on America, crediting Trump tax policies, top talent and a strong investment environment for inspiring a $55 billion U.S. investment push that spotlights growing ...
Johnson & Johnson JNJ reported 6.0% sales growth and 8.1% diluted adjusted earnings per share growth in 2025, with 2026 growth guidance of 6.7% for sales and 6.9% for diluted adjusted EPS at the ...
Johnson & Johnson (NYSE:JNJ) and Eli Lilly (NYSE:LLY) are utilizing Nvidia (NVDA) technology to either enhance their products or assist in the development of new treatments, the chipmaker's CEO said ...
Despite strong recent performances, some will point to multiple challenges Johnson & Johnson is facing. First, several of its medicines have been targeted by government-led drug price negotiations.
Johnson & Johnson grew out of an 1876 lecture by Dr. Joseph Lister on the promising results seen in his new procedure, sterile surgery. Three brothers started Johnson & Johnson, finding a factory to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results